Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting: 52-Week Data From the Phase 4 ARTISTYK Study

Deucravacitinib is a first-in-class, oral, selective, tyrosine kinase 2 inhibitor approved in multiple countries for the treatment of adults with moderate to severe plaque psoriasis [1][2][3][4] Deucravacitinib has demonstrated robust long-term efficacy and a consistent safety profile through 5 years of treatment in two global phase 3 studies in patients with moderate to severe plaque psoriasis 5-7 ARTISTYK (NCT05701995), a phase 4, placebo-controlled study evaluated the effect of deucravacitinib on quality of life (QoL) in patients with moderate to severe plaque psoriasis, a wide range of body surface area (BSA) involvement, and largely or extremely impaired QoL, who were treated in the community setting -At Week 16, deucravacitinib significantly improved QoL in this population, meeting the primary and all key secondary endpoints 8 Objective To report ARTISTYK Week 52 patient-reported outcomes, and clinical efficacy and safety results Methods Study design Patients aged 18 years with 3% BSA involvement, static Physician Global Assessment (sPGA) score 3, and Dermatology Life Quality Index (DLQI) score >5 were randomized 2:1 to receive deucravacitinib or placebo for 16 weeks (Figure 1) -Randomization was stratified by body weight (90 kg vs <90 kg) and baseline BSA (3%-10% vs >10%) At Week 16, patients randomized to placebo switched to deucravacitinib; patients randomized to deucravacitinib continued treatment through Week 52 This was a 52-week intervention study with an additional 4-week safety follow-up